Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX for urinary incontinence due to neurogenic detrusor overactivity in multiple sclerosis
2012-000957-30Phase 3Completed
- Sponsor
- Allergan
- Start
- Jun 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in detrusor hyperreflexia (DH) and multiple sclerosis (MS) comparing BOTOX 100 U intradetrusor with Placebo intradetrusor (2 arms). Primary endpoint: Urinary incontinence episodes over 3-day bladder diary. Started Jun 2012; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
detrusor hyperreflexia (DH)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2012-000957-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000957-30.